FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR/MSS Colorectal Cancer

NCT07446465 · clinicaltrials.gov ↗

PHASE4

Phase

NOT_YET_RECRUITING

Status

42

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Cancer (Locally Advanced or Metastatic)
Colorectal Cancer Microsatellite Stable (MSS)

Interventions

DRUG: Serplulimab
DRUG: Fruquintinib
DRUG: mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)

Sponsor

Ye Xu